哈佛医学院施进军教授学术报告
报告题目：Bioresponsive Nanotechnologies for RNA Delivery and Vaccine Development
报告人：Jinjun Shi，PhD,
Center for Nanomedicine, Brigham and Women’s Hospital， Harvard Medical School
时间：2018年8月27 日(周一) 上午9：00
地点：唐敖庆楼C258会议室
举办单位：新葡的京集团8814
艾滋病疫苗国家工程实验室
分子酶学工程教育部重点实验室
吉林省生物化学与分子生物学会
报告人简介:
Dr. Shi holds an academic appointment of Associate Professor at Harvard Medical School and is a faculty member in the Center for Nanomedicine at Brigham and Women’s Hospital. He has published over 50 peer-reviewed papers and holds over 45 patents/patent applications worldwide. He has also received many awards, such as the K99/R00 Career Development Award from National Institutes of Health, the Movember Challenge Award and the Young Investigator Award from Prostate Cancer Foundation, and others. Dr. Shi and his team have successfully developed various bioresponsive nanoparticle (NP) platforms including lipid-polymer hybrid NPs (PNAS 2015, PNAS 2016, Theranostics 2017), hybrid NPs (Nature BME 2018), pH-responsive and tumor-targeting/penetrating NPs (Angew Chem 2016, 2018, ACS Nano 2017, Nano Lett 2017) to address the challenges involved in systemic RNA delivery and efficacy to solid tumors (Nature Rev Cancer 2017). Dr. Shi’s lab is now utilizing the hybrid NPs for development of mRNA-based synthetic vaccines for cancer therapy and the development of polymeric nanoparticles for immuno-nanotherapeutics has formed the Selecta Biosciences company and resulted in the first-in-kind clinical trials of synthetic nanoparticle vaccines for different diseases.
